Twin-targeted antibody medication have confirmed their value in blood cancers, however the subject is working to enhance the security and efficacy of this strategy. Merck is getting a contender from Curon Biopharmaceutical that might have functions in each oncology and immunology. Merck is paying $700 million up entrance for world rights to Curon's CN201, a bispecific antibody in early scientific […]